Trade Mark Journal No.2026/026 26 June 2026

UK00004401698 12 June 2026 (5)

BYSTEAPIX

International priority date claimed: 17 December 2025 (United States of America) (99553113)

Class 5: Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations.

Amgen Inc.

Representative: Stevens Hewlett & Perkins